Ketotifen Sopharma (Ketotifen Hydrogen Fumarate)

Ketotifen works by stabilizing mast cells, which limits the release of histamine and other inflammatory mediators. In addition, it blocks H1 histamine receptors, reducing the physiological response to any histamine that is released. This dual action helps control allergic and asthmatic symptoms.

The dosage of Ketotifen Sopharma is determined by the prescribing clinician based on the patient’s age, condition severity, and response to therapy. No fixed regimen is provided here; the prescriber will set the appropriate dose and schedule.

Safety data for ketotifen in pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and import documentation.

Ketotifen differs from many second‑generation antihistamines because it also stabilizes mast cells, offering both antihistaminic and anti‑inflammatory effects. While agents like cetirizine primarily block H1 receptors, ketotifen may provide added benefit in asthma prophylaxis, though it can be more sedating.

Ketotifen Sopharma should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use.

Ketotifen Sopharma is taken orally, usually in tablet form, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow the dosing schedule provided by the healthcare professional.

Serious adverse reactions, although rare, include hepatotoxicity, severe skin reactions such as Stevens‑Johnson syndrome, blood dyscrasias, cardiac arrhythmias, and anaphylaxis. Patients should be advised to seek immediate medical attention if they experience signs of liver injury, severe rash, unexplained bleeding, or breathing difficulties.

Ketotifen Sopharma is contraindicated in individuals with known hypersensitivity to ketotifen or any of its excipients. Caution is also advised for patients with severe hepatic impairment, uncontrolled asthma, or those taking medications that may cause dangerous interactions, such as strong CYP3A4 inhibitors.